The syndrome of cardiac cachexia
Introduction
It has very long been recognised that significant weight loss and wasting are important features of advanced chronic heart failure (CHF). This dates back 2300 years to the school of medicine of Hippocrates (about 460–370 BC) on the island of Cos, when it was stated that: “The flesh is consumed and becomes water,…, the shoulders, clavicles, chest and thighs melt away. This illness is fatal,…” [1]. The term cachexia is of Greek origin, derived from the words kakos (meaning: bad) and hexis (meaning: condition). Cachexia is a process of muscle wasting and weight loss that occurs in several different chronic disorders and is also part of the ageing process [2], being almost always associated with a poor prognosis.
Cardiac cachexia is a serious complication of CHF which, until relatively recently, has been little investigated [3]. The available knowledge concerning the presence of general weight loss in CHF patients, its pathogenesis—with particular emphasis on the immunological and neurohormonal abnormalities present in this condition—and the potential treatment strategies for cardiac cachexia will be reviewed.
Section snippets
Definition of cardiac cachexia
The problems of research into cardiac cachexia start with the definition of cardiac cachexia. Research groups have extensively investigated the wasting process in different conditions, but there is still no consensus with regard to the best definition of cachexia. Body composition analyses with body fat and lean tissue estimation and anthropometric measurements (skinfold thickness, arm muscle circumference), calculations of predicted percent ideal mass matched for sex, age and height (e.g.
Epidemiology
It is widely recognised that the prevalence of chronic heart failure (CHF) is increasing. This has been attributed to improved survival in patients with coronary artery disease, the use of drug therapy prolonging life in patients with established CHF, and a strong correlation between CHF and age in populations with increasing longevity [12]. The natural and perioperative morbidity and mortality of patients with cardiac cachexia is higher than that of non-cachectic patients [9], [13]. The New
Etiology
Historically, three distinct mechanisms were thought to be responsible for the development of cardiac cachexia: (a) malabsorption and metabolic dysfunction, (b) dietary deficiency and (c) loss of nutrients via the urinary or digestive tracts. Pittman and Cohen in 1964 were the first to analyse extensively the pathogenesis of the syndrome of cardiac cachexia [16]. They proposed the development of cellular hypoxia as being the principal pathogenic factor leading to less efficient intermediary
Inflammatory cytokine activation
There is now considerable evidence to suggest that neurohormonal and immune mechanisms may play a central role in the pathogenesis of cardiac cachexia, which is likely to have a dramatic effect on the way that this condition is managed in the future [3], [28], [29], [30]. The immune system is the body’s natural defence mechanism against infection and other stresses. There are several different components to this system which interact with each other in a complex manner and may be involved in
Neuroendocrine abnormalities
A variety of secondary changes occur when heart failure becomes chronic (i.e. after 3 or 6 months) and are a response predominantly to the impaired cardiac function, although some of these secondary changes may develop consequent upon the drugs used in the treatment of heart failure. These secondary changes include general neurohormonal activation with stimulation of the sympathetic nervous system, the renin–angiotensin–aldosterone-axis, and the natriuretic peptide system. Initially, these
Body composition alterations
Patients with CHF characteristically have evidence of muscle atrophy [76], [77], being present in up to 68% of patients in certain studies [22]. Muscle weakness and early fatigue are two of the main symptoms experienced by CHF patients, and in the largest series reported to date (n=101) we found muscle weakness and fatigue to occur mainly in patients with NYHA class 3 and 4 [78], and cachectic subjects [79]. A loss of lean body mass is known to predict prognosis in cancer and AIDS [80].
Clinical implications
The detection of wasting in a CHF patient is an ominous sign. As cardiac cachexia is a multifactorial disorder characterised by an imbalance of catabolic and anabolic body systems (Fig. 4), it is unlikely that any single agent will be completely effective in treating this condition and the targeting of different pathways will be necessary.
Conclusions
Diseases that have a high priority in national health care programmes need to be: (i) common, (ii) detectable, and (iii) effectively treatable. Chronic heart failure has a prevalence of about 1–2% in the population [12], [124] which appears to be on the increase. Cachectic CHF patients represent a significant proportion of CHF patients (about 10–15%), with this condition being readily detectable. A long-term aim is to be able to predict the development of cardiac cachexia and to stop the
Acknowledgements
SDA is supported with a postgraduate fellowship from the Max Delbrück Centrum for Molecular Medicine, Berlin, Germany.
References (124)
- et al.
Geriatric cachexia: the role of cytokines
Am J Clin Nutr
(1999) - et al.
Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation
Chest
(1999) - et al.
Wasting as independent risk factor for mortality in chronic heart failure
Lancet
(1997) - et al.
Prevalence and haemodynamic correlates of malnutrition in severe congestive heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy
Am J Cardiol
(1989) Surgical treatment of patients with cardiac cachexia. An analysis of factors affecting operative mortality
Chest
(1994)- et al.
Nutritional support in cardiac cachexia
J Thorac Cardiovasc Surg
(1977) Syndromes of cardiac cachexia and the cachectic heart: current perspective
Prog Cardiovasc Dis
(1987)- et al.
Circulating interleukin-6 in severe heart failure
Am J Cardiol
(1997) - et al.
The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endothelin-1
Int J Cardiol
(2000) - et al.
Elevated soluble CD14 receptors and altered cytokines in chronic heart failure
Am J Cardiol
(1997)
Endotoxin and immune activation in chronic heart failure: a prospective cohort study
Lancet
Pyrexia, procalcitonin, immune activation and survival in cardiogenic shock: the potential importance of bacterial translocation
Int J Cardiol
Monocyte activation in congestive heart failure due to coronary artery disease and idiopathic dilated cardiomyopathy
Int J Cardiol
The endotoxin-lipoprotein hypothesis
Lancet
High tumour necrosis factor-alpha levels are associated with exercise intolerance and neurohormonal activation in chronic heart failure patients
Cytokine
Leptin serum levels in cachectic heart failure patients. Relationship with tumor necrosis factor-alpha system
Int J Cardiol
Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD)
J Am Coll Cardiol
IL-6: insights into novel biological activities
Clin Immunol Immunopathol
Loss of bone mineral in patients with cachexia due to chronic heart failure
Am J Cardiol
The relationship of the erythrocyte sedimentation rate to inflammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors
J Am Coll Cardiol
The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure
J Am Coll Cardiol
Plasma norepinephrine as an indicator of sympathetic neural activity in clinical cardiology
Am J Cardiol
Angiotensin II induces apoptosis of adult ventricular myocytes in vitro
J Mol Cell Cardiol
Norepinephrine turnover and energy expenditure in Pima Indian and white men
Metabolism
Free fatty acid kinetics and oxidation in congestive heart failure
Am J Cardiol
Energy expenditure and symptom severity in men with heart failure
Am J Cardiol
Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting
J Am Coll Cardiol
Abnormalities of skeletal muscle in patients with chronic heart failure
Int J Cardiol
Skeletal muscle function and its relation to exercise tolerance in chronic heart failure
J Am Coll Cardiol
Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS
Am J Clin Nutr
Potassium depletion and tissue loss in chronic heart disease
Lancet
Osteoporosis and bone morbidity in cardiac transplant recipients
Am J Med
Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation
J Am Coll Cardiol
Reduction of insulin-like growth factor-I expression in the skeletal muscle of noncachectic patients with chronic heart failure
J Am Coll Cardiol
Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance
J Am Coll Cardiol
Congestive heart failure: clinical management by use of continuous nasoenteric feeding
Am J Clin Nutr
Effects of physical training in chronic heart failure
Lancet
Exercise limitation in chronic heart failure: central role of the periphery
J Am Coll Cardiol
Diseases of heart in works of Hippocrates
Br Heart J
Increased concentrations of tumor necrosis factor in ‘cachectic’ patients with severe chronic heart failure
Br Heart J
Elevated circulating levels of tumor necrosis factor in severe chronic heart failure
N Engl J Med
The nutrition implications of cardiac cachexia
Nutr Rev
The epidemiology of heart failure
Eur Heart J
Malnutrition in cardiac surgical patients
Arch Surg
The pathogenesis of cardiac cachexia
N Engl J Med
Gastrointestinal absorption studies in cardiac cachexia
Intens Care Med
Fat malabsorption in elderly patients with cardiac cachexia
Age Ageing
Clinical manifestation of heart failure
Cited by (258)
Cachexia Is Associated With Adverse Outcomes in Patients Admitted With Heart Failure
2023, American Journal of CardiologyCardiac Cachexia Revisited: The Role of Wasting in Heart Failure
2022, Cardiology Clinics